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event free survival was 54%. In conclusion, UCBT is an alterna- 
tive source of hematopoietic stem cells for the treatment of chil- 
dren with malignant and non-malignant diseases who lack a suit- 
able related onor. 
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For pts with hematologic diseases requiring SCT who lack a his- 
tocompatible sibling, alternative related-donors (ARD) may be 
considered. Recent evidence suggests that outcome may also 
depend upon the parental source of the mismatched (M/M) haplo- 
type. We reviewed data on 42 pts that underwent ARD-SCT at 
VGH between 01/83 and 05/02:24 males and 18 females with a 
median age of 36 years. Diagnoses included AML (13 pts), CML 
(11 pts), ALL (8 pts) and other (10 pts). Fourteen pts had good 
risk disease. HLA testing was serologic until DNA techniques 
were instituted for class I (02/01) and class II (03/93) typing. 
Donor/recipient were phenotypic matches (PM)(3 pts), one-anti- 
gen M/M (36 pts; A-locus 19 pts, B-locus 6 pts, DR-locus 11 pts) 
or two-antigen M/M. Donors included a sibling (31 pts), a parent 
(8 pts), a child (1 pt) or a first cousin (2 pts). Stem cell source was 
bone marrow in 38 pts, blood in 3 pts or both in 1 pt. Forty pts 
initially engrafted; the remaining 2 pts were rescued with autolo- 
gous (1 pt) or allogeneic (1 pt) blood cells. One pt experienced late 
graft failure requiring a second SCT from the original donor. 
Nine pts died of acute/chronic GVHD, 2 pts from infection and 5 
frmn other causes. Seven pts died of recurrent disease. Nineteen 
pts (45%) remain alive (17 pts in CR, 2 pts in relapse) with a 
median followup of 8.8 (0.3-13.i) years. Pts having had a BMT 
from a one-antigen A-M/M or PM donor (Group 1, n=22) have a 
5 year overall smwival (OAS) of 63 %, treatment related mortality 
(TRM) of 25% and relapse rate (RR) of 16%. For all other pts 
(Group 2) OAS is 19% (p=0.01), TRM is 71% (p=0.01) and RR is 
45% (p=0.05). Incidence of acute GVHD for Group 1 and Group 
2 pts was similar[73% and 65%, respectively (p=0.4)]. There were 
more good-risk pts in Group 1 than in Group 2 (48% vs 20%, 
p=0.10). Five pts received SCT from sibling donors mismatched 
for noninherited maternal antigens (N1MA), 2 of whom are alive 
at 9.8 and 8 years respectively. Two pts received SCT from a sib- 
l ing donor mismatched for noninher i ted paternal antigens 
(NIPA), both of whom have died. ARD-SCT pts that are PM or 
one-antigen A-locu M/M with their donor appear to have out- 
comes similar to that reported for histocompatible siblings. Due 
to low pt nmnbers, the influence of parental donation and the use 
of a sibling with NIMA (rather than N[PA) couldl not be deter- 
mined. 
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Potential applications of neural stem cells (NSC) in syngeneic 
and allogeneic progenitor cell transplantation models requires 
understanding of expression of MHC nmlccules and the ability of 
T cells and NK cells to recognize this progenitor population. 
Cells from the cortices of day 13 embryonic (El3) B6 (I I-2 b) mice 
were explanted and culture(] in serum free N2 media with basic 
fibroblast growth fiactor to select for NSC. Flow cytometric analy- 
sis of cells from P2 through P17 cultures using anti-MHC class 1 
and II mAb showed marginal evels of MI IC H-2K and H-2D 
class I and H-2IA class II expression. However, t itration of 
mr lFN 7 in NSC cultures demonstrated that MHC molecules 
could be strongly upregulated following addition of 3 ng/ml 
mrIFN 7 for 60 hours. To assess the susceptibility of NSC with 
marginal versus high levels of MHC expression to lysis by CTL 
and NK populations, 4 hour 51Cr release assays employing 
untreated and mrlFN 7 treated NSC target cells were performed. 
Results showed that untreated NSC were not recognized by 
BALB/c (H-2 d) allospecific anti-H-2 b CTL, consistent with the 
anti-MHC class I mAb findings. However, upregulation of class I
and II products on both early and later passaged NSC resulted in 
their efficient lysis by CTL. NK  cells were prepared from syn- 
geneic B6 or allogeneic BALB/c mice. Although NK cells effec- 
tively ~lled control YAC-1 target cells, they did not ~11 MHC 
deficient (or expressing) NSC targets. IL 2 augmented NK effec- 
tor ceils also failed to lyse NSC target cells. The findings suggest 
that following transplant of NSC into syngeneic recipients, these 
progenitor cells may not be susceptible to clearance by host NK 
ceils. Their lack of MHC expression may also help to shield such 
cells from immediate host allogeneic T cell recognition. 
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Much more stem cell sources for allogeneic hematopoietic stem 
ceil transplantation (HST) have been available in this decade such 
as unrelated onors from marrow bank and cord blood bank in 
addition to HLA identical siblings. However, in cases of the 
urgent settings, transplant from haplo-identical related donors is 
the only choice for HST. A multi-center retrospective study is 
conducted to evaluate the feasibility of haplo-identical CD34 pos- 
itive cell transplant from related donors with more than 2 HLA 
loci mismatch. Between 1996 and 2001, a total of 25 patients with 
a variety of hematological malignancy received HST from haplo- 
identical related donors after CD34 positive cell selection. Patient 
mean age was 29 years old ranging from 17 to 69. Two patients 
with ALL/CR1 and 1 MDS (RA) patient were classified as a low 
risk group and 22 as a high risk group with advanced stage which 
is above CRI including 9 cases of second transplantation. All 
patients received positively selected CD34 peripheral blood stem 
cells isolated by CliniMACS (n=15) or Isolex 50 (n=10) system. 
Nineteen patients were conditioned with a conventional TBI con- 
taining regimen and 6 with a reduced-intensity regimen (RIST). 
GVHD prophylaxis were as follows; cyclosporine-based in 18, 
tacrolimus-based in 7 and MMF was added in 3 cases. Primary 
engraftment failure was observed in 6 out of 25 patients. Out of 6 
cases in RIST group, 3 patients were rejected. Later rejection 
after engraftment in day 28 was seen in 1 out of 19 patients evalu 
able. Sepsis with bacterial infection was seen in 9 patients, 2 of 
whom died. Fungal infections occurred in 9 patients, 2 of whom 
died. Regimen-related toxicity (RRT) was also highly observed, 3
patients died of RRT. Three cases died of lethal GVHD and 5 
cases of tumor progression. Eight of 9 second transplant cases 
died within 120 days. The estimated probability of relapse free 
survival (RFS) at 1 year was 23.3 % in all patients, 33.3 % (n=3) 
in the low-risk group and 21.6% in the high risk group (n=22). 
Engraftment failure, infectious disease, RRT and tumor progres- 
sion were the major cause of death. These data indicate that the 
nmre immunosnppressive regimen for engraftment, infection and 
tumor control at transplant are important to obtain better esults. 
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The role of alternative, unrelated (UD) or HLA mismatched 
related (nunrd) HSC donors for acute and chronic lymphoid 
102 
